Recent studies have found that the receptor for advanced glycation end products (RAGE) can reduce insulin sensitivity in tissues critical for glucose metabolism through mediated downregulation of the AMPK downregulation of the Akt signaling pathway, Silencing the signals transmitted by this receptor may be a therapeutic strategy, and the use of RAGE antagonists could potentially improve insulin receptor signaling and enhance insulin sensitivity in patients with impaired glucose tolerance (71). The gene discussed is INS; the disease is Impaired glucose tolerance.